You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A daily client check-in system for outpatient substance abuse treatment

    SBC: COG ANALYTICS, LLC            Topic: NIDA

    Abstract Alcohol and illicit drug use remain highly prevalent in the US, and epidemiological surveillance surveys estimate that over 20.6 million individuals (~ 8% of the US population) meet standard diagnostic thresholds for substance use disorders (SAMHSA, 2011). Outpatient substance abuse treatment is the predominate method of treatment in the US for SUDs, typically involving intermittent cont ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. A High-Throughput Human Metabolic Stability Assay Chip for Early-Stage Drug Disco

    SBC: Solidus Biosciences, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Solidus Biosciences, Inc. in partnership with the University of California, Berkeley, and Rensselaer Polytechnic Institute are proposing to address a critical need in drug safety technology through its proprietary meta bolic stability chip (or Metabolizing Enzyme Stability Assay Chip, or MesaChip) for high-throughput analysis of drug candidate metabolism. The ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  3. a novel cardiovascular stent for the intrinsic reduction of restenosis and thromb

    SBC: VASCULAR PROFLIX, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): One-third of adults in the U.S. and throughout the world suffer from some form of cardiovascular disease (CVD). The use of bare-metal coronary stents (BMS) for the treatment of CVD increased by 147% from 1996 to 2000, s uch that 65-80% of treatments now involve stent implantation. Unfortunately restenosis limits the success of BMS in approximately 30-51% of pat ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  4. ASAP-YS: Adaptive Screening and Assessment of Psychopathology

    SBC: CASIA SOFTWARE, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): ASAP-YS: Adaptive Screening and Assessment of Psychopathology. Project Summary: This Small Business Technology Transfer (STTR) Phase I proposal will develop and test a new computerized adaptive self-assessment measure: the Adaptive Screening and Assessment of Psychopathology-Youth Self-informant (ASAP-YS). This is a computer-assisted self-interview (A-CASI) fo ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  5. Clinical Translation of Augmented Reality Visualization for Laparoscopic Surgery

    SBC: IGI TECHNOLOGIES, INC            Topic: NCI

    DESCRIPTION (provided by applicant): The overall objective of the proposed research is to fully develop and conduct clinical translation of a novel technology that provides minimally invasive surgeons an ability to visualize exposed organ surfaces as wellas structures hidden by them, together with a true appreciation of depth. A long-standing need in minimally invasive laparoscopic surgery has bee ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Comprehensive Genotyping for Susceptibility to Metabolic Muscle Disease

    SBC: JK AUTOIMMUNITY, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of this project is to develop a large-scale genotyping tool for metabolic muscle disease that can be applied to certain high risk groups in order to prevent life-threatening symptoms that are fast becoming a public health problem. The triggering of life-threatening metabolic muscle diseases by environmental factors such as drugs, viral infections, e ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  7. Computer-based Prescription Opioid Abuse Prevention for Adolescents

    SBC: HEALTHSIM, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Recreational use of prescription opioids among adolescents is a significant and growing public health concern and has been referred to as an emerging epidemic in the U.S. Abuse of prescription opioids among adolescents has been estimated to have increased approximately 542 percent in the past decade, making prescription opioids the second most commonly abused ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  8. Developing a Nrf2 activator for the treatment of COPD

    SBC: CUREVEDA, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Chronic obstructive pulmonary disease (COPD) is a major cause of mortality and morbidity worldwide. In the US alone, the disease afflicts ~13 million people and is the third-leading cause of death. Cigarette smoking isthe primary risk factor for COPD, initiating a persistent and progressive inflammatory immune response. Respiratory infections and pollutants can ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Developing a Nrf2 activator for the treatment of scleroderma

    SBC: CUREVEDA, LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): Scleroderma is a devastating autoimmune disease with a chronic course, involving the overproduction of collagen leading to fibrosis of the skin and connective tissues. The disease has a range of symptoms including pain,stiffness and swelling of the joints, shortness of breath and gastrointestinal complications. More than 50% of patients with the aggressive form ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Development and in vitro validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 105

    DESCRIPTION provided by applicant Sanfilippo disease mucopolysaccharidosis type III MPS III is a devastating neurodegenerative lysosomal storage disorder of childhood for which there is no cure or effective treatment available The fundamental cause of MPS III is an inherited mutation in one of the enzymes required to catabolize heparan sulfate HS a glycosaminoglycan which plays importa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government